Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) generates a steady flow of news related to its late-stage biopharmaceutical pipeline in ophthalmology and neuro-ophthalmology. Company announcements highlight clinical trial milestones, regulatory designations, capital markets activity, and scientific presentations that are relevant for investors and observers tracking developments in optic neuropathies and retinal disease.
Recent news releases describe the advancement of Privosegtor, a peptoid small-molecule neuroprotective candidate, into the PIONEER registrational program for optic neuritis and non-arteritic anterior ischemic optic neuropathy. Oculis has reported positive Phase 2 ACUITY data in acute optic neuritis and disclosed that Privosegtor has received Breakthrough Therapy designation from the U.S. FDA and Orphan Drug designation from the FDA and EMA. Updates often cover trial design, endpoints such as low-contrast visual acuity, and planned global enrollment.
News coverage also follows OCS-01 eye drops in Phase 3 DIAMOND studies for diabetic macular edema, including the use of the company’s OPTIREACH technology to deliver dexamethasone topically to the retina. In addition, Oculis issues releases on Licaminlimab for dry eye disease, participation in major medical meetings such as the J.P. Morgan Healthcare Conference and ophthalmology congresses, and insider transaction notifications related to restricted stock unit vesting and director share purchases.
For readers monitoring OCS, this news feed provides company-sourced updates on clinical progress, regulatory interactions, financing transactions disclosed in Form 6-K filings, and scientific data presentations. It can be a useful reference for following how Oculis advances its investigational therapies for optic neuritis, NAION, diabetic macular edema, and dry eye disease over time.
Oculis (Nasdaq: OCS) announced management will participate in investor conferences in April 2026, including a company presentation at the Needham Healthcare Conference on April 14, 9:30 AM ET, and one-on-one meetings at Van Lanschot Kempen Life Sciences Conference on April 15-16.
The company highlighted upcoming pivotal readouts: OCS-01 DIAMOND Phase 3 topline results due June 2026, Licaminlimab PREDICT-1 topline planned late 2026, and Privosegtor holding FDA Breakthrough and EMA PRIME designations for optic neuritis.
Oculis (Nasdaq: OCS) announced that Privosegtor received EMA PRIME designation for optic neuritis on March 31, 2026, following a January 2026 FDA Breakthrough Therapy designation and existing Orphan Drug status from both EMA and FDA.
EMA support reflects positive Phase 2 ACUITY visual, anatomical and biological results; Oculis is advancing the global PIONEER registrational program, with PIONEER-1 initiated in Q4 2025.
Oculis (NASDAQ:OCS) on March 27, 2026 announced annual equity incentive awards granted to a member of its executive committee.
The notification covers an executive equity award and accompanies an attached manager-transaction notice dated March 2026.
Oculis (Nasdaq: OCS) will present Phase 2 ACUITY results for Privosegtor at NANOS 2026 on March 23, 2026, highlighting improved low‑contrast visual acuity and neuroprotective structural and biological effects in acute optic neuritis.
The company noted FDA Breakthrough Therapy designation for optic neuritis and said it initiated the PIONEER registrational program, with PIONEER‑1 started in Q4 2025.
Oculis (OCS) announced notifications of ordinary share purchases by a member of its Board of Directors.
The company attached transaction notices dated March 12, 2026 and March 13, 2026, naming board member Christina Ackermann.
Oculis (OTC:OCS) announced notifications dated March 11, 2026, disclosing annual equity incentive awards granted to members of the company's executive committee.
The notice lists attached manager transaction notifications for Riadh Sherif, Sylvia Cheung, and Pall Ragnar Johannesson regarding their 2026 annual awards.
Oculis (OCS) announced notifications of transactions by persons discharging managerial responsibilities related to the vesting and settlement of RSUs previously granted to company directors.
Named directors with RSU vesting notifications include Riad Sherif (6 March 2026), Robert Warner (4 March 2026), Arshad Khanani (4 and 6 March 2026), Christina Ackermann (4 March 2026) and Anthony Rosenberg (4 March 2026).
Oculis (NASDAQ: OCS) announced that it has filed its audited consolidated IFRS financial statements for the 2025 fiscal year and the MD&A on Form 20-F with the SEC on March 5, 2026. Attachments include the 2025 consolidated financial statements, the MD&A and ESEF reporting files.
Oculis (Nasdaq: OCS) announced management participation in investor conferences in March 2026, presenting updates on its late-stage ophthalmology and neuro-ophthalmology pipeline.
Highlights include breakthrough therapy designation for Privosegtor in optic neuritis, DIAMOND Phase 3 topline timing for OCS-01 in Q2 2026, and the PREDICT-1 licaminlimab program.
Oculis (OCS) published a notification on March 4, 2026 regarding the vesting and settlement of restricted stock units (RSUs) previously granted to a director. The disclosure names Arshad Khanani and references an RSU vesting event dated 28 February 2026.